Gene expression control
AssigneeAventis Pharma S.A.
InventorsClaude Helene, Carine Giovannangeli
Life of this patent
Estimating the term…
Abstract
The present invention relates to new vectors, pharmaceutical compositions containing them, and their therapeutical uses. More particularly, it relates to new molecules capable of acting, in a very selective and efficacious way, on the expression of genes.
Claims20
A recombinant vector, wherein the vector comprises a double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNA in a target cell.
A recombinant viral vector selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, cytomegalovirus and vaccinia virus, wherein the viral vector comprises more than one double stranded DNA sequence coding for an RNA which forms a triple helix with a single-stranded target nucleic acid, and signals permitting the transcription of the RNAs in a target cell.
An RNA comprising:
- (a) a first region which forms a double helix with an oligopurine region of a single-stranded target nucleic acid,
- (b) a second region which forms a triple helix with the double helix formed between the first region and the oligopurine region of the single stranded target nucleic acid,
- (c) a first oligonucleotide arm connecting the first and second regions,
- (d) a third region which forms a double helix with an oligopyrimidine region of the single-stranded target nucleic acid,
- (e) a fourth region which forms a triple helix with the double helix formed between the third region and the oligopyrimidine region of the single-stranded target nucleic acid, and
- (f) a second oligonucleotide arm connecting the third and fourth region, wherein two triple helices are formed.
Dependencies are inferred from the claim text.